Meghana covers early stage innovation in the life sciences for MedCity News. Previously, she's worked for Reuters, Crain’s Detroit Business, the San Diego Business Journal, the Detroit Metro Times, the Detroit Free Press and WDET, a Detroit-based National Public Radio affiliate. Meghana studied biochemistry and molecular biology at Penn State University and spent five years as a self-described "research peon in a schizophrenia genetics lab."
Sparrow Pharmaceuticals won the therapeutics category as part of this year’s Best of INVEST awards. Corticosteroids are an important anti-inflammatory treatment agent for a variety of medical conditions – ranging from autoimmune to cancer to organ transplants. However, chronic use of these drugs can lead to a similarly wide range of side effects. Sparrow Pharmaceuticals has brushed the dust […]
In a statement, LifeSci Advisors says it "is dedicated to transforming itself into a model for promoting gender diversity" in the industry.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Also, a reverse merger by Synta Pharmaceuticals and Madrigal Pharmaceuticals will create a company that focuses on non-alcoholic steatohepatitis and Kaiser Permanente has launched a biobank to develop new diagnoses and treatment plans.
Indeed, the growth rate is supposed to increase each year through 2020, the report says - thanks largely to drugs targeting cancer.
A new IMS report found that the 2015 late phase pipeline includes 2,320 novel products - and projects that more than 200 new drugs will be approved by 2020.
[youtube https://www.youtube.com/watch?v=Q_N3Qf4LgOc] Dr. Akhil Saklecha of Artiman Ventures spoke on camera at this week’s INVEST conference in Chicago about the healthcare business opportunities in Asia – and some of the challenges that entrepreneurs and investors face. You can watch the video above. Artiman Ventures has six funds – four early stage, two growth stage, and all […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The organization's all about generic drugs - but unlike, say, Martin Shkreli, Bloom's big idea is to repurpose existing drugs and lessen the overall costs of healthcare.
"I'm a skeptic of public market valuations, but a true believer in biotechnology," said Hans Hinrichs, managing director of Silicon Valley Bank's Life Sciences and Healthcare Group. "We're probably sitting on the biggest opportunity in the history of investment."
However, medical devices haven't fared nearly as well. While biotech investment hit a 21-year high in 2015, medical device funding has dropped to just a quarter of healthcare dollars.
Corporate venture investment has emerged as an important alternative to more traditional healthcare funding avenues. However, there's still a dearth of information about their activity.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Also, Intel healthcare guru Eric Dishman has been selected to lead up the Precision Medicine Initiative.
In the wake of its relationship with Martin Shkreli, KaloBios' new CEO Cameron Durrant "wants to clean up the messy legacy and start afresh," he said.
GE Ventures and Mayo Clinic have teamed up to spin out a new software company, called, Vitruvian Networks, that focuses on bringing the "internet of things" to the cell and gene therapy space.
Every week, we compile the most trafficked and thoughtful stories on MedCity News. Most influential: IBM Watson Health's Anil Jain on issues like alert fatigue, its partnerships, and the benefits of being cloud-based.
Counsyl's layoffs are in sales support, marketing, design and engineering.